Knochenspezifische Radium-223-Dichlorid-Therapie: Symptomatisches, ossär metastasiertes, kastrationsresistentes Prostatakarzinom

R. Tauber; J. Gschwend; K. Scheidhauer; M. Eiber; M. Krönke

doi:10.1007/s00120-016-0300-5

Knochenspezifische Radium-223-Dichlorid-Therapie: Symptomatisches, ossär metastasiertes, kastrationsresistentes Prostatakarzinom

Translated title of the contribution: Bone-specific therapy with radium-223 dichloride: Castration-resistant prostate cancer with symptomatic bone metastases

R. Tauber, J. Gschwend, K. Scheidhauer, M. Eiber, M. Krönke

Technical University of Munich

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Radium-223 dichloride (Xofigo®, Alpharadin) is approved for the treatment of metastatic castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastases. As a calcium mimetic, it is integrated into osteoplastic bone lesions and emits alpha particles with high energy which leads to local destruction of tumor cells. In the 2013 published ALSYMPCA trial, a significant advantage for overall survival and quality of life in comparison to placebo was found. Recent data suggest an increased potential in combination with next generation hormonal treatment.

Translated title of the contribution	Bone-specific therapy with radium-223 dichloride: Castration-resistant prostate cancer with symptomatic bone metastases
Original language	German
Pages (from-to)	24-31
Number of pages	8
Journal	Urologe - Ausgabe A
Volume	56
Issue number	1
DOIs	https://doi.org/10.1007/s00120-016-0300-5
State	Published - 1 Jan 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00120-016-0300-5

Cite this

@article{cee3bf92d2fd498780d031315a2a8b7a,

title = "Knochenspezifische Radium-223-Dichlorid-Therapie: Symptomatisches, oss{\"a}r metastasiertes, kastrationsresistentes Prostatakarzinom",

abstract = "Radium-223 dichloride (Xofigo{\textregistered}, Alpharadin) is approved for the treatment of metastatic castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastases. As a calcium mimetic, it is integrated into osteoplastic bone lesions and emits alpha particles with high energy which leads to local destruction of tumor cells. In the 2013 published ALSYMPCA trial, a significant advantage for overall survival and quality of life in comparison to placebo was found. Recent data suggest an increased potential in combination with next generation hormonal treatment.",

keywords = "Alpha ray therapy, Bone metastases, Castration-resistant prostate cancer, Next generation hormonal treatment, Radionuclide therapy, Thrombocytopenia",

author = "R. Tauber and J. Gschwend and K. Scheidhauer and M. Eiber and M. Kr{\"o}nke",

note = "Publisher Copyright: {\textcopyright} 2017, Springer Medizin Verlag Berlin.",

year = "2017",

month = jan,

day = "1",

doi = "10.1007/s00120-016-0300-5",

language = "Deutsch",

volume = "56",

pages = "24--31",

journal = "Urologe - Ausgabe A",

issn = "0340-2592",

publisher = "Springer Medizin",

number = "1",

}

TY - JOUR

T1 - Knochenspezifische Radium-223-Dichlorid-Therapie

T2 - Symptomatisches, ossär metastasiertes, kastrationsresistentes Prostatakarzinom

AU - Tauber, R.

AU - Gschwend, J.

AU - Scheidhauer, K.

AU - Eiber, M.

AU - Krönke, M.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Radium-223 dichloride (Xofigo®, Alpharadin) is approved for the treatment of metastatic castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastases. As a calcium mimetic, it is integrated into osteoplastic bone lesions and emits alpha particles with high energy which leads to local destruction of tumor cells. In the 2013 published ALSYMPCA trial, a significant advantage for overall survival and quality of life in comparison to placebo was found. Recent data suggest an increased potential in combination with next generation hormonal treatment.

AB - Radium-223 dichloride (Xofigo®, Alpharadin) is approved for the treatment of metastatic castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastases. As a calcium mimetic, it is integrated into osteoplastic bone lesions and emits alpha particles with high energy which leads to local destruction of tumor cells. In the 2013 published ALSYMPCA trial, a significant advantage for overall survival and quality of life in comparison to placebo was found. Recent data suggest an increased potential in combination with next generation hormonal treatment.

KW - Alpha ray therapy

KW - Bone metastases

KW - Castration-resistant prostate cancer

KW - Next generation hormonal treatment

KW - Radionuclide therapy

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=85008502075&partnerID=8YFLogxK

U2 - 10.1007/s00120-016-0300-5

DO - 10.1007/s00120-016-0300-5

M3 - Artikel

C2 - 28058455

AN - SCOPUS:85008502075

SN - 0340-2592

VL - 56

SP - 24

EP - 31

JO - Urologe - Ausgabe A

JF - Urologe - Ausgabe A

IS - 1

ER -

Knochenspezifische Radium-223-Dichlorid-Therapie: Symptomatisches, ossär metastasiertes, kastrationsresistentes Prostatakarzinom

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this